Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 8/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 7/20 | 1.00 |
| ▸ | STS | P08842 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 2/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | SHBG | P04278 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | SNCA | P37840 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone SCHEMBL29621709 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT | |
| Estrone SCHEMBL13153301 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT | |
| Estrone SCHEMBL29373834 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT | |
| Estrone SCHEMBL31398229 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT | |
| Estrone SCHEMBL12054811 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT | |
| Estrone SCHEMBL157262 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT | |
| Estrone SCHEMBL7831317 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT | |
| Estrone SCHEMBL15079288 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT | |
| Estrone SCHEMBL12822081 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT | |
| Estrone SCHEMBL10039359 | 1.00 | CYP19A1 (1.00) | CYP19A1HSD17B1STSLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105606685-A | Preparation method and application of oestrone molecular imprinting electrochemical sensor | UNIV FUJIAN AGRICULTURE & FORESTRY | 2016-05-25 | — | — | CN | claimed |
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | disclosed |
| CN-105606685-A | Preparation method and application of oestrone molecular imprinting electrochemical sensor | UNIV FUJIAN AGRICULTURE & FORESTRY | 2016-05-25 | — | — | CN | disclosed |
| CN-104758806-A | Decocted extract for treating coronary heart disease and preparation method thereof | LI CHUANWEI | 2015-07-08 | — | — | CN | disclosed |
| WO-2014191852-A1 | SYSTEM AND METHOD OF DELICATE MEMBRANE CONDENSED PHASE MEMBRANE INTRODUCTION MASS SPECTROMETRY (CP-MIMS) | GILL, CHRISTOPHER (CA) | 2014-12-04 | — | — | WO | disclosed |
| WO-2008039360-A9 | ULTRASOUND-INDUCED DESTRUCTION OF TRACE-LEVEL ESTROGEN HORMONES IN AQUEOUS SOLUTIONS | UNIV VILLANOVA (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008039360-A2 | ULTRASOUND-INDUCED DESTRUCTION OF TRACE-LEVEL ESTROGEN HORMONES IN AQUEOUS SOLUTIONS | VILLANOVA UNIVERSITY (US) | 2008-04-03 | — | — | WO | disclosed |
| US-7335650-B2 | Composition | STERIX LIMITED (GB) | 2008-02-26 | — | — | US | disclosed |
| US-7119082-B2 | 11β-long-chain-substituted 19-nor-17α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-10 | — | — | US | disclosed |
| US-20030229059-A1 | 11Beta-long-chain-substituted 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring | SCHERING AG (DE) | 2003-12-11 | — | — | US | disclosed |
| CN-1456107-A | Healthy beverage | YU BEISHAN (CN) | 2003-11-19 | — | — | CN | disclosed |
| US-20020193444-A1 | Composition | POTTER BARRY VICTOR LLOYD (GB) | 2002-12-19 | — | — | US | disclosed |
| EP-0734531-A1 | METHODS AND MEANS FOR DETERMINING THE FEMALE FERTILE PERIOD | Abbott Laboratories (US) | 1996-10-02 | — | — | EP | disclosed |
| WO-1995016920-A1 | METHODS AND MEANS FOR DETERMINING THE FEMALE FERTILE PERIOD | ABBOTT LABORATORIES (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229059-A1 | 11Beta-long-chain-substituted 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring | HSD17B11, CYP17A1, CYP19A1 | ESR1 107/4885CYP19A1 3/4885HSD17B1 10/4885 |
| US-20020193444-A1 | Composition | SULT1A1, SDHB, SULT2A1 | ESR1 2183/4885CYP19A1 217/4885HSD17B1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.